Premium
The interferon‐β1b clinical trial and its implications for other trials
Author(s) -
Paty Donald W.
Publication year - 1994
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410360726
Subject(s) - clinical trial , medicine , placebo , magnetic resonance imaging , radiology , pathology , alternative medicine
This trial was monitored by both clinical and magnetic resonance imaging (MRI) methods. Clinical effect was a 30% reduction in relapse rate in the group treated with a high dose. The MRI activity rate was reduced by a median of 70% in both treatment groups. The burden of disease measure showed a clear‐cut dose effect in the 2‐year analysis. Future trials must be monitored by MRI. In addition, placebo controls will continue to be necessary in most trials, especially if long‐term effects are to be measured.